Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference
May 08, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 28, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ To Report First Quarter 2023 Financial Results
April 24, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 14, 2023 16:01 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update
March 06, 2023 16:01 ET
|
Ocular Therapeutix, Inc.
Presented Positive 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD at the Angiogenesis, Exudation, and...
Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference
February 28, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results
February 21, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
February 11, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10 CSFT and BCVA measurements at 10 months were...
Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones
January 06, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
Dextenza® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year ...